Glen Eagle Advisors, LLC Cti Biopharma Corp Transaction History

Glen Eagle Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	N/A	-10 Closed	0 $0
Q4 2019 Aug 13, 2024	BUY	$0.72 - $1.64 $172 - $393	240 Added 2400.0%	250 $395,000
Q1 2019 Aug 13, 2024	BUY	$0.9 - $1.37 $9 - $13	10 New	10 $10,000
Q2 2018 Aug 13, 2024	SELL	$3.81 - $5.26 $110 - $152	-29 Reduced 74.36%	10 $50,000
Q1 2018 Aug 14, 2024	BUY	$2.7 - $4.06 $27 - $40	10 New	10 $39,000
Q1 2018 Aug 13, 2024	BUY	$2.7 - $4.06 $78 - $117	29 Added 290.0%	39 $39,000
Q3 2017 Aug 13, 2024	BUY	$3.12 - $3.65 $31 - $36	10	10 $32,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Glen Eagle Advisors, LLC with notifications on news.